Sage Journals: Discover world-class research

Abstract

The authors report further analysis of a six-year retrospective chart review of multiple sclerosis (MS) patients prescribed interferon-beta (IFNB) in British C olumbia, C anada. A ctions and outcomes taken when 284/835 (34%) of the patients developed de novo elevated aminotransferases are presented; 239/284 (84%) of patients were continued on treatment despite these elevations; 216/246 (88%) of patients reaching grade 1 toxicity (greater than the upper limit of normal) continued IFNB treatment; of these, 167/216 (77%) returned to within normal limits. O f the 22/29 (76%) reaching grade 2 toxicity (> 2.5 times the upper limit of normal) and continuing treatment, 14/22 (64%) returned to within the normal range. O ne of the nine patients reaching grade 3 toxicity (> 5 times the upper limit of normal) was allowed continue treatment and their aminotransferase levels returned to within normal limits. However, one patient reaching grade 3 toxicity went on to develop liver failure (previously reported).

Keywords

adverse drug reaction aminotransferase interferon-beta liver multiple sclerosis pharmacovigilance

Get full access to this article

View all access options for this article.

References

Stricker B ed. Drug-induced hepatic injury, second edition. Amsterdam: Elsevier , 1992: 402-405.

Durelli L , Ferrero B , Oggero A , Verdun E , Ghezzi A , Montanari E et al. Liver and thyroid function and autoimmunity during interferon-beta1b treatment for Multiple Sclerosis . Neurology 2001; 57: 1363-1370 .

Tremlett HL , Yoshida E , Oger J. Liver injury associated with the IFNBs for MS: a comparison between IFNB-1b(sc), IFNB-1a (sc) and IFNB-1a (im) . Neurology 2004 62: 628-631 .

Anonymous . National Cancer Institute . Cancer Therapy Evaluation Program. Common toxicity criteria, Version 2. DCTD, NCI, NIH, DHHS. Revised March 1998, published April 1999 (http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf; accessed 19 November 2002).

Yoshida EM , Rasmussen SL , Steinbrecher UP , Erb SR , Scuda-more CH , Chung SW et al. Fulminant liver failure during interferon beta treatment of Multiple Sclerosis . Neurology 2001; 56: 1416-1416 .

Benichou C , The Council for International Organisations of Medical Sciences (CIOMS) . Criteria of drug-induced liver disorders . J Hepatol 1990; 11: 272-276 .

Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver . Sem Liver Dis 2002; 22: 145-155 .

Renton KW. Alterations of drug biotransformation and elimination during infection and inflammation . Pharmacol Therapeutics 2001; 92: 147-163 .

Elevated aminotransferases during treatment with interferon-beta for multiple sclerosis: actions and outcomes

Abstract

Keywords

Get full access to this article

References